title: A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
abstract: OBJECTIVE
  Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Sorafenib is considered the standard of care for patients with advanced HCC.
  
  
  METHODS
  We conducted a retrospective analysis of our cancer center's experience with sorafenib in patients with advanced HCC. Eligible patients were required to have measurable disease and were allowed to have been refractory (with documented progression) to prior systemic therapies before starting on sorafenib.
  
  
  RESULTS
  Twenty-six patients (median age = 56 years) who were treated at the Ohio State University with sorafenib were included in this study. Thirty-eight percent had exposure to prior systemic therapy. The median time to tumor progression was 5.4 months and the median overall survival 7 months. For the patients with exposure to prior systemic therapy, the median time to tumor progression was 9.1 months and is the median overall survival 9.83 months. There were no unexpected toxicities.
  
  
  CONCLUSIONS
  Sorafenib has interesting activity and acceptable tolerability in patients with advanced HCC, including those who failed prior therapies.
authors.affiliation: Center for Biostatistics, Columbus, Ohio, USA.
authors.forename: Stephanie M
authors.initials: SM
authors.lastname: Balsom
authors.forename: Xiaobai
authors.initials: X
authors.lastname: Li
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Trolli
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Rose
authors.forename: Mark
authors.initials: M
authors.lastname: Bloomston
authors.forename: Tushar
authors.initials: T
authors.lastname: Patel
authors.forename: Tanios S
authors.initials: TS
authors.lastname: Bekaii-Saab
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib